These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19331230)

  • 1. Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1.
    Pectasides D; Papaxoinis G; Nikolaou M; Valavanis C; Aravantinos G; Fountzilas G; Tamvakis N; Pectasides E; Lekka I; Arapantoni-Dadioti P; Zizi A; Ghiconti I; Economopoulos T
    Anticancer Res; 2009 Feb; 29(2):737-44. PubMed ID: 19331230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.
    Mazumdar M; Bacik J; Tickoo SK; Dobrzynski D; Donadio A; Bajorin D; Motzer R; Reuter V; Bosl GJ
    J Clin Oncol; 2003 Jul; 21(14):2679-88. PubMed ID: 12860944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of MDR1-expression in testicular germ cell cancer.
    Schrader AJ; Seger M; Konrad L; Olbert P; Hegele A; Hofmann R; Heidenreich A
    Exp Oncol; 2007 Sep; 29(3):212-6. PubMed ID: 18004247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
    Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
    Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors.
    Albers P; Orazi A; Ulbright TM; Miller GA; Haidar JH; Donohue JP; Foster RS
    Mod Pathol; 1995 Jun; 8(5):492-7. PubMed ID: 7545814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
    Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
    BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological markers of cisplatin resistance in advanced testicular germ cell tumours.
    García-Velasco A; Durán I; García E; Tarón M; Ballestín C; Castellanos D; Cortés-Funés H; Paz-Ares L
    Clin Transl Oncol; 2012 Jun; 14(6):452-7. PubMed ID: 22634534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
    Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
    Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
    Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
    Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment.
    Mandoky L; Szende B; Géczi L; Bodrogi I; Kásler M; Bak M
    Anticancer Res; 2008; 28(3A):1641-9. PubMed ID: 18630521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.
    Olofsson SE; Nodin B; Gaber A; Eberhard J; Uhlén M; Jirström K; Jerkeman M
    PLoS One; 2015; 10(3):e0121300. PubMed ID: 25811459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
    Gupta D; Shidham V; Holden J; Layfield L
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):267-74. PubMed ID: 11127918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors. Implications for risk-adjusted therapy].
    Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW; Engelmann UH
    Urologe A; 1999 Mar; 38(2):168-78. PubMed ID: 10231939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.
    Callagy GM; Pharoah PD; Pinder SE; Hsu FD; Nielsen TO; Ragaz J; Ellis IO; Huntsman D; Caldas C
    Clin Cancer Res; 2006 Apr; 12(8):2468-75. PubMed ID: 16638854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
    Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
    Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
    Sestakova Z; Kalavska K; Smolkova B; Miskovska V; Rejlekova K; Sycova-Mila Z; Palacka P; Obertova J; Holickova A; Hurbanova L; Jurkovicova D; Roska J; Goffa E; Svetlovska D; Chovanec M; Mardiak J; Mego M; Chovanec M
    Mutat Res Genet Toxicol Environ Mutagen; 2020; 854-855():503200. PubMed ID: 32660824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.